UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Letter: the definition of budesonide dependence in microscopic colitis—authors’ reply

Alimentary pharmacology & therapeutics, 2017-09, Vol.46 (6), p.636-636

2017

Volltextzugriff (PDF)

P734 Super-responders in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1375-i1376

2024

Volltextzugriff (PDF)

Editorial: biologic therapies for primary sclerosing cholangitis—more disappointment than promise? Authors’ reply

Alimentary pharmacology & therapeutics, 2018-09, Vol.48 (5), p.578-579

2018

Volltextzugriff (PDF)

P540 Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1062-i1064

2024

Volltextzugriff (PDF)

P786 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i919-i920

2023

Volltextzugriff (PDF)

P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i568-i569

2023

Volltextzugriff (PDF)

OP10 Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s Disease: results from the U-ENDURE long-term extension

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i17-i18

2024

Volltextzugriff (PDF)

P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i574-i576

2023

Volltextzugriff (PDF)

P854 Race and ethnicity in ulcerative colitis clinical trial enrolment: a post hoc analysis of patient demographics and clinical characteristics from GEMINI 1, VARSITY, and VISIBLE 1

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i977-i979

2023

Volltextzugriff (PDF)

P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1330-i1332

2024

Volltextzugriff (PDF)

P678 Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTE

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1288-i1289

2024

Volltextzugriff (PDF)

DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i104-i106

2023

Volltextzugriff (PDF)

OP37 Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S034-S035

2021

Volltextzugriff (PDF)

OP04 Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S004-S006

2021

Volltextzugriff (PDF)

OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S033-S034

2021

Volltextzugriff (PDF)

P283 Bowel urgency in patients with moderate to severe ulcerative colitis: prevalence and correlation with clinical outcomes, biomarker levels, and health-related quality of life from U-ACHIEVE, a Phase 2b study of upadacitinib

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S240-S241

2019

Volltextzugriff (PDF)

P258 Abdominal pain and its relationship with clinical outcomes, biomarker levels, and health-related quality of life in patients with moderate to severe ulcerative colitis: data from U-ACHIEVE, a Phase 2b study of upadacitinib

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S226-S226

2019

Volltextzugriff (PDF)

P313 Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S257-S257

2019

Volltextzugriff (PDF)

DOP002 Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS study

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S030-S031

2018

Volltextzugriff (PDF)

P367 Vedolizumab and early postoperative complications in non-intestinal surgery: A case-matched analysis

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S290-S290

2018

Volltextzugriff (PDF)

OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S009-S009

2019

Volltextzugriff (PDF)

P479 Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S351-S352

2019

Volltextzugriff (PDF)

OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S021-S022

2021

Volltextzugriff (PDF)

P273 Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S238-S239

2018

Volltextzugriff (PDF)

P757 Long-term effectiveness and safety of adalimumab based on Crohn’s disease duration: Results from the PYRAMID registry

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S493-S494

2018

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieContemporary Internal Medicine

ThemaCrohn Disease - Drug Therapy

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(7)
Cholangitis, Sclerosing - Complications
(2)
Female
(2)
Inflammatory Bowel Disease
(2)
Inflammatory Bowel Diseases - Epidemiology
(2)
Male
(2)
Adolescent
(1)
Allergy And Immunology
(1)
Biological And Medical Sciences
(1)
Biomarkers - Analysis
(1)
Budesonide
(1)
Capsule Endoscopy
(1)
Cardiovascular Disease
(1)
Cause Of Death
(1)
Cholangitis
(1)
Cholangitis, Sclerosing - Epidemiology
(1)
Cohort Studies
(1)
Colitis
(1)
Colitis, Ulcerative - Complications
(1)
Colonoscopy
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Letter: the definition of budesonide dependence in microscopic colitis—authors’ reply

P734 Super-responders in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD study

Editorial: biologic therapies for primary sclerosing cholangitis—more disappointment than promise? Authors’ reply

P540 Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials

P786 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease

P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease

OP10 Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s Disease: results from the U-ENDURE long-term extension

P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis

P854 Race and ethnicity in ulcerative colitis clinical trial enrolment: a post hoc analysis of patient demographics and clinical characteristics from GEMINI 1, VARSITY, and VISIBLE 1

P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme

P678 Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTE

DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib

OP37 Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION study

OP04 Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study

OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies

P283 Bowel urgency in patients with moderate to severe ulcerative colitis: prevalence and correlation with clinical outcomes, biomarker levels, and health-related quality of life from U-ACHIEVE, a Phase 2b study of upadacitinib

P258 Abdominal pain and its relationship with clinical outcomes, biomarker levels, and health-related quality of life in patients with moderate to severe ulcerative colitis: data from U-ACHIEVE, a Phase 2b study of upadacitinib

P313 Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study

DOP002 Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS study

P367 Vedolizumab and early postoperative complications in non-intestinal surgery: A case-matched analysis

OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study

P479 Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies

OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study

P273 Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study

P757 Long-term effectiveness and safety of adalimumab based on Crohn’s disease duration: Results from the PYRAMID registry

Aktive Filter

Suchergebnisse filtern